Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — Sosei Group — UBS Healthcare Virtual Conference 2021
18 slides from Nxera Pharma's conference presentation, May 25, 2021
Slide 1: World leading drug discovery targeting GPCRs
NON – CONFIDENTIAL World leading drug discovery targeting GPCRs UBS Healthcare Virtual Conference 25 May 2021 | © Sosei Group Corporation
Slide 2: Disclaimer
Disclaimer The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the “Company”) as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed
Slide 3: World leading drug discovery targeting GPCRs
World leading drug discovery targeting GPCRs World leader in EVOLVING WITH A SPECIALIST GPCR drug discovery THERAPEUTIC FOCUS and early development Advancing a broad and deep Proprietary GPCR-targeted pipeline of over 40 partnered StaR® technology and SBDD and in-house programs across platform capab
Slide 4: We can unlock the potential of GPCRs with our StaR technology
We can unlock the potential of GPCRs with our StaR® technology GPCRs are well-known targets with StaR® enables us to unlock the potential of GPCRs via advanced significant untapped opportunity understanding of their structure and atomic/molecular interactions Unstable ~400 native GPCR GPCR PROTEINS
Slide 5: Core capabilities in drug discovery and early development, with a late-stage development team in Japan
Core capabilities in drug discovery and early development, with a late-stage development team in Japan focused on in-licensing DRUG DISCOVERY/EARLY DEVELOPMENT DRIVEN BY STAR® / SBDD ENGINE LATE STAGE DEVELOPMENT PRE-DISCOVERY DISCOVERY PRECLINICAL PH 1a PH 1b PH 2/3 APPROVAL StaR® Technology SBDD D
Slide 6: Established track record of attracting world-leading partners
Established track record of attracting world-leading partners Active Partnerships Active Spin-Out Asset Centric Vehicles NEW Upfront and milestone payments, ~$700 royalties and R&D funding ~$6 Total potential deal value of received from partners to date1 active partnerships2 million billion 1 Encomp
Slide 7: Organic growth plan driving our world-leading GPCR drug discovery
Organic growth plan driving our world-leading GPCR drug discovery OBJECTIVE ORGANIC GROWTH PLAN OBJECTIVE At least 2 new Continue to expand Preclinical Candidates expertise in GPCRs on average, Extend technology / Generate high quality every year platform leadership novel candidates OBJECTIVE OBJECT
Slide 8: Organic growth plan objectives met
Organic growth plan driving our world-leading GPCR drug discovery OBJECTIVES MET ORGANIC GROWTH PLAN OBJECTIVES MET ✓ Jan-20 – Orexin agonist ✓ H1 FY20 – Nomination of H4 scientific breakthrough, ant. candidate for Atopic triggering next tranche of Dermatitis Medicxi funding (Orexia, Inexia) ✓ H1 FY
Slide 9: Our StaR technology and SBDD platform enables productive drug discovery
Our StaR® technology and SBDD platform enables productive drug discovery and generates multiple high quality candidates LAST 10 YEARS (StaR® / SBDD GENERATED) TODAY MEDIUM TERM OUTLOOK DRUG DISCOVERY EARLY DEVELOPMENT LEAD OP TECHNOLOGY DRUG DISCOVERY 5 compounds Generated Produced Deliver at least
Slide 10: Excellent progress in collaborative drug discovery, adding three new pharma partnerships in 2020
We continued to make excellent progress in collaborative drug discovery, adding three new pharma partnerships in 2020 Partner Active Partnered Program Therapeutic Area UF / Near Term Payments Potential deal value1 2020 Collaboration and Licensing Gastrointestinal, $44m $480m+ Agreement for GPR35 ago
Slide 11: We added multiple new partnered and in-house programs to our deep pipeline
We added multiple new partnered and in-house programs to our deep pipeline, which will drive more collaborations and value creation Pre-Disc. / 20+ Preclinical development 12 Phase 1 8 Phase 2 2 Marketed 4 Discovery Multi-target GPR35 ag. CGRP ant. A2A ant. A2a ant. combo(s) Ultibro® Breezhaler® Mul
Slide 12: Potential to deliver transformative new treatments for patients
Potential to deliver transformative new treatments for patients Muscarinic M4 and M1 receptors are validated targets for psychosis and cognition Muscarinic M4 and M1 receptors represent Xanomeline, the M4/M1 preferring agonist, achieved validated targets for the treatment of psychosis human Proof of
Slide 13: HTL'878 potential to deliver transformative treatments for patients
HTL’878 potential to deliver transformative treatments for patients Schizophrenia remains a huge unmet medical need Large market with …Despite no innovation Huge opportunity for HTL’878 blockbuster sales profiles… in 70 years Current treatments use the same ~20M SZ patients worldwide MOA from the 19
Slide 14: HTL'878 is now the focus of increased capital allocation
HTL’878 is now the focus of increased capital allocation from us to enable acceleration, whilst maintaining investment other programs Muscarinic budget Program Compound Stage FY2021 FY2022 R&D allocation* M4 agonist HTL’878 Ph 1 Preparation for Phase 2 Phase 2 Phase 2 50% start trial activity Data
Slide 15: Strategic growth plan driving corporate value expansion
Strategic growth plan driving corporate value expansion OBJECTIVE STRATEGIC GROWTH PLAN OBJECTIVE MET Add new technology Capital raise capabilities to our completed to pursue SBDD platform deals in 2021 P P Seek out revenue- Invest / collaborate in generating opportunities novel technologies OBJECTI
Slide 16: Summary Financial Highlights (FY20 and 1Q 21)
Summary Financial Highlights (FY20 and 1Q 21) Revenue ($m) Cash Earnings ($m) Cash ($m) 89.2 82.8 386.5 26.1 27.2 140.3 12m to 31-Dec-19 12m to 31-Dec-20 12m to 31-Dec-19 12m to 31-Dec-20 As of 31-Dec-19 As of 31-Dec-20 Stepped-up R&D investment 10.7 11.4 in HTL’878 to drive value as 386.5 we seek g
Slide 17: Priority objectives for FY2021
Priority objectives for FY2021 Progress organic Execute strategic Commitment to sustainable growth plan growth plan development goals • Extend technology / platform • Transformative revenue- • Promote sustainable ESG leadership generating acquisition practices and policies across • Generate high qua
Slide 18: Thank you for your attention
Thank you for your attention Chris Cargill Chief Financial Officer IR@soseiheptares.com SOSEI HEPTARES PMO Hanzomon 11F Steinmetz Building North West House 2-1 Kojimachi, Chiyoda-ku Granta Park, Cambridge 119 Marylebone Road Tokyo 102-0083 CB21 6DG London NW1 5PU Japan United Kingdom United Kingdom